Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.

@article{Novakovi2017NeuroendocrineTO,
  title={Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.},
  author={Sabina Novakovi{\'c} and Anamarija Kova{\vc} Pei{\'c} and Hrvoje Holik and Bo{\vz}ena Coha},
  journal={Acta clinica Belgica},
  year={2017},
  volume={72 6},
  pages={
          461-464
        }
}
Imatinib mesylate (IM), a tyrosine kinase inhibitor, is the treatment of choice in patients with chronic myeloid leukemia (CML). It is considered a very safe drug, with mostly mild and reversible side effects. Lately, it has been suggested that adverse events may occur after a long term. We report a case of a 72-year-old woman diagnosed with blastic phase… CONTINUE READING